FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number: 3235-0											
Estimated average burden											
hours ner resnons	e 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Borgeson Blake					2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [ RXRX ]										all app	tor	ng Per	10% Ov	vner
(Last)	(Last) (First) (Middle) C/O RECURSION PHARMACEUTICALS						3. Date of Earliest Transaction (Month/Day/Year) 11/28/2023								Officer (give title below)			Other (s	specify
41 S. RIO GRANDE STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					oplicable
(Street) SALT LAKE CITY UT 84101												X	Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
					Rul	Rule 10b5-1(c) Transaction Indication													
(City)	City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - N	Ion-Deriva	tive \$	Secui	rities	Ac	quire	d, Di	sposed of	f, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye				Execution (ear) if any		emed ion Date, /Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquired (A) or (D) (Instr. 3, 4 a		ind 5) Se Be Ov		Securities Beneficially Owned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price		Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Class A Common Stock 11/28/202					)23				S <sup>(1)</sup>		11,447	D	\$6.719	95 <sup>(2)</sup> 7,39		395,973		D	
		Tal	ble II	l - Derivati (e.g., pu							posed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Der Sec	rice of ivative urity tr. 5)	tive derivative ity Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.
- 2. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from \$6.35 to \$7.03 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

## Remarks:

/s/ Jonathan Golightly, attorney-in-fact

11/30/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.